The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.

New research by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with the GSK Vaccines Institute ...

The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is ...

Revolune today announced a partnership with Concept Life Sciences to help biopharma and life sciences customers reassess, transfer, and ...

Edge Copper Corporation was pleased to announce the appointment of Chris Ballard as Vice President of Exploration, effective November 1, 2026. Mr. Ballard brings direct experience at the Company's 100 ...

MammoLink joins Mammogen’s KATELYN-ERIN trial, expanding community access to a prospective study evaluating blood-based RNA biology for breast ...

CDK2/CycE1 is a cancer target linked to therapy resistance, and no inhibitor is reported to block formation of the complex specifically. Isogenica selected 192 unique VHHs against ...

A peer-reviewed study of 230 human clinical samples found that a CRISPR-assisted nanodroplet assay identified NTM species and ...

Boost ROI with validated, automated multiplex assays, AI analytics and research partnerships that improve throughput, reproducibility and biomarker relevance.Dublin, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ...

Meridian Bioscience Inc. has earned a Health Canada license for its Alethia CMV assay, expanding its existing Alethia menu.

Streamlined kit design cuts hands-on time, reduces error sources and conserves precious biological samples for ...